Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) rose 6.1% on Tuesday . The company traded as high as $5.96 and last traded at $5.78. Approximately 663,255 shares changed hands during trading, a decline of 54% from the average daily volume of 1,453,813 shares. The stock had previously closed at $5.45.
Wall Street Analysts Forecast Growth
ATYR has been the topic of a number of recent research reports. Leerink Partners initiated coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Wednesday, June 4th. Finally, Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $18.60.
View Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Stock Down 4.2%
The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $3.60. The company has a market capitalization of $462.82 million, a price-to-earnings ratio of -5.53 and a beta of 0.88.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. Equities analysts expect that Atyr PHARMA INC will post -0.91 EPS for the current year.
Institutional Investors Weigh In On Atyr PHARMA
Large investors have recently modified their holdings of the stock. Group One Trading LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $26,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $37,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Atyr PHARMA in the 1st quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $39,000. Finally, XTX Topco Ltd bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $40,000. 61.72% of the stock is currently owned by institutional investors.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Further Reading
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
